-
公开(公告)号：EP1029549A1
公开(公告)日：2000-08-23
申请号：EP99942707.3
申请日：1999-09-03
发明人： AGUILAR RUBIDO, Julio César , MUZIO GONZALEZ, Verena Lucila , GUILLEN NIETO, Gerardo Enrique , PENTON ARIAS, Eduardo , LEAL ANGULO, Maria de Jesús , PICHARDO DIAZ, Dagmara Calle 222 No. 2716 , IGLESIAS PEREZ, Enrique Edificio 25 Apto. 103 , HERRERA BUCH, Antonieta , SANDEZ OQUENDO, Bélquis , MUSACCHIO LASA, Alexis , QUINTANA VAZQUEZ, Diógenes , CROMBET MENENDEZ, Lissete
CPC分类号： A61K39/21 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/53 , A61K2039/54 , A61K2039/543 , A61K2039/545 , A61K2039/55583 , C12N2740/16034
摘要： The present invention is related to the medical field, and in particular to the use of new formulations of adjuvants with vaccine antigens. The technical object of the invention is the development of formulations which are capable of potentiating the immune response of the organism to vaccines of nucleic acids. In order to attain this objective, a formulation has been developed which contains as fundamental components the vaccine nucleic acid and acemannan in adequate proportions, in addition to stabilizing and preservative agents. The formulations of the invention are applicable to the pharmaceutical industry as vaccine formulations both for human and animal use.
摘要翻译： 本发明涉及医疗领域，特别涉及使用具有疫苗抗原的佐剂的新制剂。 本发明的技术目的是开发能够增强生物体对核酸疫苗的免疫应答的制剂。 为了达到这个目标，除了稳定剂和防腐剂之外，已经开发出一种配方，其中含有足够比例的疫苗核酸和acemannan作为基本组分。 本发明的制剂适用于作为用于人类和动物使用的疫苗制剂的制药工业。
-
公开(公告)号：EP0971737A1
公开(公告)日：2000-01-19
申请号：EP98907815.9
申请日：1998-03-05
发明人： AGUILAR RUBIDO, Julio César , MUZIO GONZALEZ, Verena Lucila , LEAL ANGULO, Maria de Jesús , GUILLEN NIETO, Gerardo Enrique , PENTON ARIAS, Eduardo , VELIZ RIOS, Gloria , PICHARDO DIAZ, Dagmara , HERRERA BUCH, Antonieta , IGLESIAS PEREZ, Enrique , CRUZ RICONDO, Luis Javier , CARMENATE PORTILLA, Tania , MESA PARDILLO, Cirse , HECHAVARRIA GAY, Maydel , DIAZ MARTINEZ, Maylin , MADRAZO PINOL, Juan Joel
IPC分类号： A61K39/39 , A61K39/29 , A61K39/295
CPC分类号： A61K39/095 , A61K39/12 , A61K39/292 , A61K2039/54 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/55588 , C12N2730/10134 , Y10S514/885 , Y10S977/906
摘要： The present invention relates to the medical field, particularly to the use of new formulations of adjuvants as vaccinal antigenes. The technical objective of the present invention is precisely the development of formulations capable of raising and/or modulating the immune response of the organism to vaccinal antigenes at serum and mucus levels. In order to attain such objective, a formulation has been developed which contains as fundamental components the surface antigene of the B hepatitis virus and the acemanane in adequate proportions. As an extension of such result, formulations have been developed wherein: a) HBsAg is used as carrier of homologous and heterologous antigenes; b) systems for transmitting particulate antigens and c) soluble antigens, in combination with the acemanane in specific proportions. The formulations of this invention are applicable to the pharmaceutical industry as vaccinal formulations both for human and veterinary use.
-
公开(公告)号：EP0971737B1
公开(公告)日：2005-05-11
申请号：EP98907815.9
申请日：1998-03-05
发明人： AGUILAR RUBIDO, Julio César , MUZIO GONZALEZ, Verena Lucila , LEAL ANGULO, Maria de Jesús , GUILLEN NIETO, Gerardo Enrique , PENTON ARIAS, Eduardo , VELIZ RIOS, Gloria , PICHARDO DIAZ, Dagmara , HERRERA BUCH, Antonieta , IGLESIAS PEREZ, Enrique , CRUZ RICONDO, Luis Javier , CARMENATE PORTILLA, Tania , MESA PARDILLO, Cirse , HECHAVARRIA GAY, Maydel , DIAZ MARTINEZ, Maylin , MADRAZO PINOL, Juan Joel
IPC分类号： A61K39/39 , A61K39/29 , A61K39/295
CPC分类号： A61K39/095 , A61K39/12 , A61K39/292 , A61K2039/54 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/55588 , C12N2730/10134 , Y10S514/885 , Y10S977/906
摘要： The present invention relates to the medical field, particularly to the use of new formulations of adjuvants as vaccinal antigenes. The technical objective of the present invention is precisely the development of formulations capable of raising and/or modulating the immune response of the organism to vaccinal antigenes at serum and mucus levels. In order to attain such objective, a formulation has been developed which contains as fundamental components the surface antigene of the B hepatitis virus and the acemanane in adequate proportions. As an extension of such result, formulations have been developed wherein: a) HBsAg is used as carrier of homologous and heterologous antigenes; b) systems for transmitting particulate antigens and c) soluble antigens, in combination with the acemanane in specific proportions. The formulations of this invention are applicable to the pharmaceutical industry as vaccinal formulations both for human and veterinary use.
-
-
搜索结果
3 条记录 (耗时 0.019 秒)
